1-Propyl thioisobutyrate | 90467-79-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硫代羧酸及其衍生物
• 英文名称: 1-Propyl thioisobutyrate
• 英文别名: S-propyl 2-methylpropanethioate
• CAS: 90467-79-1
• 化学式: C₇H₁₄OS
• 分子量: 146.254
• InChiKey: KJSOVOXNLTWWPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-Isopropyl-1,3-oxathian 在 二叔丁基过氧化物 作用下， 以 氯苯 为溶剂， 反应 4.0h， 以65%的产率得到1-Propyl thioisobutyrate
  参考文献：
  名称：

  Zorin, V. V.; Batyrbaev, N. A.; Zlot-skii, S. S., Journal of Organic Chemistry USSR (English Translation), 1984, vol. 20, p. 347 - 352

  摘要：

  DOI：

文献信息

• Isatoic anhydride derivatives and applications thereof
  申请人：The University of North Carolina at Charlotte

  公开号：US10179175B2

  公开（公告）日：2019-01-15

  Isatoic anhydride derivatives having an N-substituent which includes a quaternary ammonium group are useful for labeling and/or functionalizing a target material and/or for coupling materials together. The isatoic anhydride derivatives of the present disclosure can be advantageously water soluble, easily prepared and purified. Isatoic anhydride derivatives useful in the present disclosure preferably have at least one chemically reactive group or at least one binding group or at least one detectable label. Anthranilate derivatives made from the isatoic anhydrides derivatives or otherwise and kits including the isatoic anhydride derivatives are also disclosed.

  具有包括季铵基团的 N 取代基的异酸酐衍生物可用于标记和/或官能化目标材料和/或将材料耦合在一起。本公开的异酸酐衍生物可溶于水，易于制备和纯化。本公开中有用的异酸酐衍生物最好具有至少一个化学反应基团或至少一个结合基团或至少一个可检测标签。此外，还公开了由异酸酐衍生物或其他衍生物制成的蒽酸衍生物以及包括异酸酐衍生物的试剂盒。
• Cysteamine prodrugs
  申请人：Children's Hospital Medical Center

  公开号：US11357750B2

  公开（公告）日：2022-06-14

  Described herein are prodrugs of cysteamine and pharmaceutically acceptable salts, solvates, and esters thereof. Also described herein are pharmaceutical compositions comprising prodrugs of cysteamine, or pharmaceutically acceptable salts, solvates, and esters thereof, and methods of treatment comprising administering prodrugs of cysteamine, or pharmaceutically acceptable salts, solvates, and esters thereof.

  本文描述了半胱胺原药及其药学上可接受的盐、溶液和酯。本文还描述了包含半胱胺原药或其药学上可接受的盐、溶液和酯的药物组合物，以及包括施用半胱胺原药或其药学上可接受的盐、溶液和酯的治疗方法。
• ZORIN, V. V.;BATYRBAEV, N. A.;ZLOTSKIJ, S. S.;RAXMANKULOV, D. L., ZH. ORGAN. XIMII, 1984, 20, N 2, 387-393
  作者：ZORIN, V. V.、BATYRBAEV, N. A.、ZLOTSKIJ, S. S.、RAXMANKULOV, D. L.

  DOI：——

  日期：——
• KASATKINA A. A.; BATYRBAEV N. A., HOB. REAKTIVY HA OSNOVE ATSETALEJ, ORTOEHFIROV, IX ANALOGOV I PROIZVODNYX+
  作者：KASATKINA A. A.、 BATYRBAEV N. A.

  DOI：——

  日期：——
• Aldolase-inhibiting aromatic compounds
  申请人：Dax Chantal

  公开号：US20090137532A1

  公开（公告）日：2009-05-28

  The invention relates to novel aldolase-inhibiting compounds that can be advantageously used as medicaments (in therapeutic doses), especially for treating certain cancers, due to the inhibition efficacy thereof. An inventive compound corresponds to general formula (I) wherein the aldehyde group (—CHO) and the phenol group (—OH) are linked to two carbon atoms adjacent to the same aromatic chain, i.e., the first aromatic chain, and R is a phosphate group or a phosphate group mimetic linked to a carbon atom of the second aromatic chain.